Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of pirtobrutinib, a non-covalent (reversible) Bruton's tyrosine kinase...